sibmedСибирский научный медицинский журналСибирский научный медицинский журнал2410-25122410-2520ИЦиГ СО РАН10.15372/SSMJ20200202sibmed-365Research ArticleОБЗОРЫREVIEWSИнтерфероны лямбда – возможности терапевтического примененияInterferons lambda – therapeutic applicationКихтенкоН. А.KikhtenkoN. A.

Николай Андреевич Кихтенко

630091, г. Новосибирск, Красный просп., 52

Nikolai A. Kikhtenko

630091, Novosibirsk, Krasnyi av., 52

dr.kikhtenko@gmail.comОлейникЛ. А.OleynikL. A.

Лариса Алексеевна Олейник

630091, г. Новосибирск, Красный просп., 52

Larisa A. Oleynik

630091, Novosibirsk, Krasnyi av., 52

larysa.oleynik@gmail.comМакаровВ. К.MakarovV. K.

Вячеслав Константинович Макаров

630091, г. Новосибирск, Красный просп., 52

Vyacheslav K. Makarov

630091, Novosibirsk, Krasnyi av., 52

kaffarm@yandex.ruНагорскаяЕ. П.NagorskayaE. P.

Елизавета Петровна Нагорская

630091, г. Новосибирск, Красный просп., 52

Elizaveta P. Nagorskaya

630091, Novosibirsk, Krasnyi av., 52

kaffarm@yandex.ruМадоновП. Г.MadonovP. G.

Павел Геннадьевич Мадонов, д.м.н.

630091, г. Новосибирск, Красный просп., 52

Pavel G. Madonov, doctor of medical sciences

630091, Novosibirsk, Krasnyi av., 52

pmadonov@yandex.ruНовосибирский государственный медицинский университет Минздрава РоссииРоссияNovosibirsk State Medical University of Minzdrav of RussiaRussian Federation2020010520204021523Copyright © Кихтенко Н.А., Олейник Л.А., Макаров В.К., Нагорская Е.П., Мадонов П.Г., 20202020Кихтенко Н.А., Олейник Л.А., Макаров В.К., Нагорская Е.П., Мадонов П.Г.Kikhtenko N.A., Oleynik L.A., Makarov V.K., Nagorskaya E.P., Madonov P.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://sibmed.elpub.ru/jour/article/view/365

Интерфероны – группа белковых молекул, обладающих широким спектром воздействия на организм. Интерферон лямбда (интерферон III типа) открыт сравнительно недавно – около 20 лет назад – и является относительно малоизученным. Изучение его свойств и механизмов действия вызывает большой интерес, поскольку, обладая сходством с интерферонами I типа, интерферон лямбда имеет ряд отличительных особенностей, которые создают предпосылки для расширения его клинического применения. В частности, интерферон лямбда продуцируется не всеми клетками организма, а значит, имеет более целенаправленное воздействие, чем интерфероны I типа, что снижает системные побочные эффекты. Обзор посвящен биологической активности экзогенного интерферона лямбда, рассматриваются механизмы противовирусной, противоопухолевой, противогрибковой, иммуномодулирующей активности, а также возможности его применения в клинической практике при таких заболеваниях, как синдром Шегрена, атопическая астма, аутоиммунный артрит, различные опухоли, а также в отношении самых разных, как РНК-, так и ДНК-содержащих вирусов, которые атакуют поверхности анатомических барьеров дыхательных путей, желудочно-кишечного тракта, гематоэнцефалического барьера и печени. Также рассматривается пегилированный рекомбинантный интерферон лямбда, для которого начаты клинические исследования, продемонстрировавшие более высокий профиль безопасности пегилированного интерферона лямбда по сравнению с пегилированным интерфероном альфа.

Interferons are a group of protein molecules with a broad spectrum of effects on the human body. Interferon lambda (type III interferon) was discovered comparatively recently about 20 years ago and its action is still poorly understood. However, the study of its properties and mechanisms of action is of great interest, since it not only has similarity with type I interferons, but has a number of distinctive features that create prerequisites for expanding its clinical use. Particularly, interferon lambda is not produced by all cells of the body, and therefore has a more targeted effect and lower systemic side effects than type I interferons. This review considers the biological activity of exogenous interferon lambda: the mechanisms of its antiviral, antitumor, antifungal and immunomodulatory activity. The possibility of its use in clinical practice for the treatment of such diseases as Sjogren’s syndrome, atopic asthma, autoimmune arthritis, various tumors, as well as against a various of RNA- and DNA-containing viruses that attack the anatomical barrier surface of the respiratory tract, gastrointestinal tract, blood-brain barrier and liver is discussed. This review also considers pegylated recombinant interferon lambda. Recent clinical studies have demonstrated a higher safety profile of pegylated interferon lambda compared with pegylated interferon alpha.

интерфероны лямбдаклиническое применениеиммунобиологическая терапияпротивовирусная терапияпегилированный интерферон лямбдаinterferons lambdaclinical useimmunobiologic therapyantiviral therapypegylated interferon lambdaReferencesАртамонов А.В., Бекарев А.А., Дыгай А.М., Жданов В.В., Киншт Д.Н., Мадонов П.Г., Шерстобоев Е.Ю. Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения. Пат. РФ 2678332; Опубл. 28.01.2019.АArtamonov A.V., Bekarev A.A., Dygai A.M., Zhdanov V.V., Kinsht D.N., Madonov P.G., Sherstoboev E Yu. Pegylated interferon lambda for oral administration, and method for producing same. Patent 2678332 RF; Publ. 28.01.2019. [In Russian].Григорян С.С. Интерфероны лямбда (3-й тип интерферонов) и вирусные инфекции. Интерферон-2011: сб. науч. ст. М., 2012. 512 с.Grigoryan S.S. Interferon lambda (3rd type of interferons) and viral infections. Interferon-2011: coll. sci. papers. Moscow, 2012. 512. P. 63–72. [In Russian].Мальдов Д.Г., Андронова В.Л., Григорян С.С., Исаева Е.И., Балакина А.А., Терентьев А.А., Ильичёв А.В., Галегов Г.А. Механизм действия стимфорте на герпесвирусную инфекцию. Вопр. вирусологии. 2018; 63 (5): 218–222. doi: 10.18821/0507-4088-201863-5-218-223Maldov D.G., Andronova V.L., Grigoryan S.S., Isaeva E.I., Balakina A.A., Terentev A.A., Ilichev A.V., Galegov G.A. The mechanism of stimforte action on herpesvirus infection. Voprosy virusologii = Problems of Virology. 2018; 63 (5): 218–222. [In Russian]. doi: 10.18821/0507-4088-2018-63-5-218-223Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFNlambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006; 80 (9): 4501–4509. doi: 10.1128/JVI.80.9.4501-4509.2006Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFNlambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006; 80 (9): 4501–4509. doi: 10.1128/JVI.80.9.4501-4509.2006Bandi P., Pagliaccetti N.E., Robek M.D. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J. Interferon Cytokine Res. 2010; 30 (3): 123–134. doi: 10.1089/jir.2009.0049Bandi P., Pagliaccetti N.E., Robek M.D. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J. Interferon Cytokine Res. 2010; 30 (3): 123–134. doi: 10.1089/jir.2009.0049Baños-Lara Mdel R., Harvey L., Mendoza A., Simms D., Chouljenko V.N., Wakamatsu N., Kousoulas K.G., Guerrero-Plata A. Impact and regulation of lambda interferon response in human metapneumovirus infection. J. Virol. 2015; 89 (1): 730–742. doi: 10.1128/JVI.02897-14Baños-Lara Mdel R., Harvey L., Mendoza A., Simms D., Chouljenko V.N., Wakamatsu N., Kousoulas K.G., Guerrero-Plata A. Impact and regulation of lambda interferon response in human metapneumovirus infection. J. Virol. 2015; 89 (1): 730–742. doi: 10.1128/JVI.02897-14Bartlett N.W., Buttigieg K., Kotenko S.V., Smith G.L. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J. Gen. Virol. 2005; 86 (6): 1589–1596. doi: 10.1099/vir.0.80904-0Bartlett N.W., Buttigieg K., Kotenko S.V., Smith G.L. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J. Gen. Virol. 2005; 86 (6): 1589–1596. doi: 10.1099/vir.0.80904-0Blazek K., Eames H.L., Weiss M., Byrne A.J., Perocheau D., Pease J.E., Doyle S., McCann F., Williams R.O., Udalova I.A. IFN-l resolves inflammation via suppression of neutrophil infiltration and IL1b production. J. Exp. Med. 2015; 212: 845–853. doi:10.1084/jem.20140995Blazek K., Eames H.L., Weiss M., Byrne A.J., Perocheau D., Pease J.E., Doyle S., McCann F., Williams R.O., Udalova I.A. IFN-l resolves inflammation via suppression of neutrophil infiltration and IL1b production. J. Exp. Med. 2015; 212: 845–853. doi:10.1084/jem.20140995Caine E.A., Scheaffer S.M., Arora N., Zaitsev K., Artyomov M.N., Coyne C.B., Moley K.H., Diamond M.S. Interferon lambda protects the female reproductive tract against Zika virus infection. Nat. Commun. 2019; 10 (1): 280. doi: 10.1038/s41467-01807993-2Caine E.A., Scheaffer S.M., Arora N., Zaitsev K., Artyomov M.N., Coyne C.B., Moley K.H., Diamond M.S. Interferon lambda protects the female reproductive tract against Zika virus infection. Nat. Commun. 2019; 10 (1): 280. doi: 10.1038/s41467-01807993-2Carrick D.M. Interferon lambda: an immune system factor that cancer epidemiologists should consider. J. Interferon. Cytokine Res. 2019; 39 (10). 592–593. doi: 10.1089/jir.2019.0033 [Epub ahead of print]Carrick D.M. Interferon lambda: an immune system factor that cancer epidemiologists should consider. J. Interferon. Cytokine Res. 2019; 39 (10). 592–593. doi: 10.1089/jir.2019.0033 [Epub ahead of print]Castillo-Martínez D., Juarez M., Patlán M., Páez A., Massó F., Amezcua-Guerra L.M. Type-III interferons and rheumatoid arthritis: Correlation between interferon lambda 1 (interleukin 29) and antimutated citrullinated vimentin antibody levels. Autoimmunity. 2017; 50 (2): 82–85. doi: 10.1080/08916934.2017.1289181Castillo-Martínez D., Juarez M., Patlán M., Páez A., Massó F., Amezcua-Guerra L.M. Type-III interferons and rheumatoid arthritis: Correlation between interferon lambda 1 (interleukin 29) and antimutated citrullinated vimentin antibody levels. Autoimmunity. 2017; 50 (2): 82–85. doi: 10.1080/08916934.2017.1289181Chan H.L.Y., Ahn S.H., Chang T.T., Peng C.Y., Wong D., Coffin C.S., Lim S.G., Chen P.J., Janssen H.L.A., Marcellin P., Serfaty L., Zeuzem S., Cohen D., Critelli L., Xu D., Wind-Rotolo M., Cooney E.; LIRA-B Study Team. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). J. Hepatol. 2016; 64 (5): 1011–1019. doi: 10.1016/j.jhep.2015.12.018Chan H.L.Y., Ahn S.H., Chang T.T., Peng C.Y., Wong D., Coffin C.S., Lim S.G., Chen P.J., Janssen H.L.A., Marcellin P., Serfaty L., Zeuzem S., Cohen D., Critelli L., Xu D., Wind-Rotolo M., Cooney E.; LIRA-B Study Team. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). J. Hepatol. 2016; 64 (5): 1011–1019. doi: 10.1016/j.jhep.2015.12.018Cui L., Yu F., Ma J., Pei H., Zuo L. Effects of DENV-2 infection on the expression of IL-29 in primary HUVECs cultured on hydrogel substrates. Chinese Journal of Microbiology and Immunology (China). 2015; 35 (1): 7–13. doi: 10.3760/cma.j.issn.0254-5101.2015.01.002Cui L., Yu F., Ma J., Pei H., Zuo L. Effects of DENV-2 infection on the expression of IL-29 in primary HUVECs cultured on hydrogel substrates. Chinese Journal of Microbiology and Immunology (China). 2015; 35 (1): 7–13. doi: 10.3760/cma.j.issn.0254-5101.2015.01.002Dantas A.T., Gonçalves S.M., Pereira M.C., de Almeida A.R., Marques C.D., Rego M.J., Pitta Ida R., Duarte A.L., Pitta M.G. Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29). Autoimmunity. 2015; 48 (7): 429–433. doi: 10.3109/08916934.2015.1054028Dantas A.T., Gonçalves S.M., Pereira M.C., de Almeida A.R., Marques C.D., Rego M.J., Pitta Ida R., Duarte A.L., Pitta M.G. Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29). Autoimmunity. 2015; 48 (7): 429–433. doi: 10.3109/08916934.2015.1054028Davidson S., McCabe T.M., Crotta S., Gad H.H., Hessel E.M., Beinke S., Hartmann R., Wack A. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol. Med. 2016; 8 (9): 1099–112. doi: 10.15252/emmm.201606413Davidson S., McCabe T.M., Crotta S., Gad H.H., Hessel E.M., Beinke S., Hartmann R., Wack A. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol. Med. 2016; 8 (9): 1099–112. doi: 10.15252/emmm.201606413Douam F., Soto Albrecht Y.E., Hrebikova G., Sadimin E., Davidson C., Kotenko S.V., Ploss A. Type III interferon-mediated signaling is critical for controlling live attenuated yellow fever virus infection in vivo. MBio. 2017; 8 (4): e00819-17. doi: 10.1128/mBio.00819-17Douam F., Soto Albrecht Y.E., Hrebikova G., Sadimin E., Davidson C., Kotenko S.V., Ploss A. Type III interferon-mediated signaling is critical for controlling live attenuated yellow fever virus infection in vivo. MBio. 2017; 8 (4): e00819-17. doi: 10.1128/mBio.00819-17Espinosa V., Dutta O., McElrath C., Du P., Chang Y.J., Cicciarelli B., Pitler A., Whitehead I., Obar J.J., Durbin J.E., Kotenko S.V., Rivera A. Type III interferon is a critical regulator of innate antifungal immunity. Sci. Immunol. 2017; 2 (16): eaan5357. doi:10.1126/sciimmunol.aan53Espinosa V., Dutta O., McElrath C., Du P., Chang Y.J., Cicciarelli B., Pitler A., Whitehead I., Obar J.J., Durbin J.E., Kotenko S.V., Rivera A. Type III interferon is a critical regulator of innate antifungal immunity. Sci. Immunol. 2017; 2 (16): eaan5357. doi:10.1126/sciimmunol.aan53Flisiak R., Shiffman M., Arenas J., Cheinquer H., Nikitin I., Dong Y., Rana K., Srinivasan S. A randomized study of peginterferon lambda-1a compared to peginterferon alfa-2a in combination with ribavirin and telaprevir in patients with genotype-1 chronic hepatitis C. PLoS One. 2016; 11 (10): e0164563. doi:10.1371/journal.pone.0164563Flisiak R., Shiffman M., Arenas J., Cheinquer H., Nikitin I., Dong Y., Rana K., Srinivasan S. A randomized study of peginterferon lambda-1a compared to peginterferon alfa-2a in combination with ribavirin and telaprevir in patients with genotype-1 chronic hepatitis C. PLoS One. 2016; 11 (10): e0164563. doi:10.1371/journal.pone.0164563Ha Y.J., Choi Y.S., Kang E.H., Chung J.H., Cha S., Song Y.W., Lee Y.J. Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren’s syndrome and its synergic effect with interferon-α on salivary gland epithelial cells. Clin. Exp. Rheumatol. 2018; 36 (Suppl. 112, 3): 31–40.Ha Y.J., Choi Y.S., Kang E.H., Chung J.H., Cha S., Song Y.W., Lee Y.J. Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren’s syndrome and its synergic effect with interferon-α on salivary gland epithelial cells. Clin. Exp. Rheumatol. 2018; 36 (Suppl. 112, 3): 31–40.Hausman D.F., Dodds M.G. Use of pegylated type III interferons for the treatment of hepatitis C. Patent WO2009149377A1; Publ. 10.12.2009.Hausman D.F., Dodds M.G. Use of pegylated type III interferons for the treatment of hepatitis C. Patent WO2009149377A1; Publ. 10.12.2009.Hermant P., Michiels T. Interferon-λ in the context of viral infections: production, response and therapeutic implications. J. Innate Immun. 2014; 6: 563–574. doi: 10.1159/000360084Hermant P., Michiels T. Interferon-λ in the context of viral infections: production, response and therapeutic implications. J. Innate Immun. 2014; 6: 563–574. doi: 10.1159/000360084Ilyushina N.A., Lugovtsev V.Y., Samsonova A.P., Sheikh F.G., Bovin N.V., Donnelly R.P. Generation and characterization of interferon-lambda 1-resistant H1N1 influenza A viruses. PLoS One. 2017; 12 (7): e0181999. doi: 10.1371/journal.pone.0181999Ilyushina N.A., Lugovtsev V.Y., Samsonova A.P., Sheikh F.G., Bovin N.V., Donnelly R.P. Generation and characterization of interferon-lambda 1-resistant H1N1 influenza A viruses. PLoS One. 2017; 12 (7): e0181999. doi: 10.1371/journal.pone.0181999Jounai K., Sugimura T., Ohshio K., Fujiwara D. Oral administration of Lactococcus lactis subsp. lactis JCM5805 enhances lung immune response resulting in protection from murine parainfluenza virus infection. PLoS One. 2015; 10 (3): e0119055. doi: 10.1371/journal.pone.0119055Jounai K., Sugimura T., Ohshio K., Fujiwara D. Oral administration of Lactococcus lactis subsp. lactis JCM5805 enhances lung immune response resulting in protection from murine parainfluenza virus infection. PLoS One. 2015; 10 (3): e0119055. doi: 10.1371/journal.pone.0119055Kim H.J., Jo A., Jeon Y.J., An S., Lee K.M., Yoon S.S., Choi J.Y. Nasal commensal Staphylococcus epidermidis enhances interferon-λ-dependent immunity against influenza virus. Microbiome. 2019; 7 (1): 80. doi: 10.1186/s40168-019-0691-9Kim H.J., Jo A., Jeon Y.J., An S., Lee K.M., Yoon S.S., Choi J.Y. Nasal commensal Staphylococcus epidermidis enhances interferon-λ-dependent immunity against influenza virus. Microbiome. 2019; 7 (1): 80. doi: 10.1186/s40168-019-0691-9Kim S., Kim M.J., Kim C.H., Kang J.W., Shin H.K., Kim D.Y., Won T.B., Han D.H., Rhee C.S., Yoon J.H., Kim H.J. The superiority of IFN-λ as a therapeutic candidate to control acute influenza viral lung infection. Am. J. Respir. Cell. Mol. Biol. 2017; 56 (2): 202–212. doi: 10.1165/rcmb.2016-0174OCKim S., Kim M.J., Kim C.H., Kang J.W., Shin H.K., Kim D.Y., Won T.B., Han D.H., Rhee C.S., Yoon J.H., Kim H.J. The superiority of IFN-λ as a therapeutic candidate to control acute influenza viral lung infection. Am. J. Respir. Cell. Mol. Biol. 2017; 56 (2): 202–212. doi: 10.1165/rcmb.2016-0174OCKlinkhammer J., Schnepf D., Ye L., Schwaderlapp M., Gad H.H., Hartmann R., Garcin D., Mahlakõiv T., Staeheli P. IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. Elife. 2018; 7: e33354. doi: 10.7554/eLife.33354Klinkhammer J., Schnepf D., Ye L., Schwaderlapp M., Gad H.H., Hartmann R., Garcin D., Mahlakõiv T., Staeheli P. IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. Elife. 2018; 7: e33354. doi: 10.7554/eLife.33354Koch S., Finotto S. Role of interferon-l in allergic asthma. J. Innate Immun. 2015; 7: 224–230. doi: 10.1159/000369459Koch S., Finotto S. Role of interferon-l in allergic asthma. J. Innate Immun. 2015; 7: 224–230. doi: 10.1159/000369459Kotenko S.V., Gallagher G., Baurin V.V., LewisAntes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., Donnelly R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003; 4 (1): 69–77. doi: 10.1038/ni875Kotenko S.V., Gallagher G., Baurin V.V., LewisAntes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., Donnelly R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003; 4 (1): 69–77. doi: 10.1038/ni875Lasfar A., Zloza A., Silk A.W., Lee L.Y., Cohen-Solal K.A. Interferon lambda: toward a dual role in cancer. J. Interferon Cytokine Res. 2019; 39 (1): 22–29. doi: 10.1089/jir.2018.0046Lasfar A., Zloza A., Silk A.W., Lee L.Y., Cohen-Solal K.A. Interferon lambda: toward a dual role in cancer. J. Interferon Cytokine Res. 2019; 39 (1): 22–29. doi: 10.1089/jir.2018.0046Lazear H.M., Nice T.J., Diamond M.S. Interferon-λ: immune functions at barrier surfaces and beyond. Immunity. 2015; 43 (1): 15–28. doi: 10.1016/j.immuni.2015.07.001Lazear H.M., Nice T.J., Diamond M.S. Interferon-λ: immune functions at barrier surfaces and beyond. Immunity. 2015; 43 (1): 15–28. doi: 10.1016/j.immuni.2015.07.001Lazear H.M., Daniels B.P., Pinto A.K., Huang A.C., Vick S.C., Doyle S.E., Gale M.Jr., Klein R.S., Diamond M.S. Interferon-λ restricts West Nile virus neuroinvasion by tightening the bloodbrain barrier. Sci. Transl. Med. 2015; 7: 284ra59. doi: 10.1126/scitranslmed.aaa4304Lazear H.M., Daniels B.P., Pinto A.K., Huang A.C., Vick S.C., Doyle S.E., Gale M.Jr., Klein R.S., Diamond M.S. Interferon-λ restricts West Nile virus neuroinvasion by tightening the bloodbrain barrier. Sci. Transl. Med. 2015; 7: 284ra59. doi: 10.1126/scitranslmed.aaa4304Lazear H.M., Schoggins J.W., Diamond M.S. Shared and distinct functions of type I and type III interferons. Immunity. 2019; 50 (4): 907–923. doi:10.1016/j.immuni.2019.03.025Lazear H.M., Schoggins J.W., Diamond M.S. Shared and distinct functions of type I and type III interferons. Immunity. 2019; 50 (4): 907–923. doi:10.1016/j.immuni.2019.03.025Lee S., Baldridge M.T. Interferon-lambda: a potent regulator of intestinal viral infections. Front. Immunol. 2017; 8: 749. doi: 10.3389/fimmu.2017.00749Lee S., Baldridge M.T. Interferon-lambda: a potent regulator of intestinal viral infections. Front. Immunol. 2017; 8: 749. doi: 10.3389/fimmu.2017.00749Lee S.J., Lee E.J., Kim S.K., Jeong P., Cho Y.H., Yun S.J., Kim S., Kim G.Y., Choi Y.H., Cha E.J., Kim W.J., Moon S.K. Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A. PLoS One. 2012; 7 (9): e40267. doi: 10.1371/journal.pone.0040267Lee S.J., Lee E.J., Kim S.K., Jeong P., Cho Y.H., Yun S.J., Kim S., Kim G.Y., Choi Y.H., Cha E.J., Kim W.J., Moon S.K. Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A. PLoS One. 2012; 7 (9): e40267. doi: 10.1371/journal.pone.0040267Li L., Fu F., Xue M., Chen W., Liu J., Shi H., Chen J., Bu Z., Feng L., Liu P. IFN-lambda preferably inhibits PEDV infection of porcine intestinal epithelial cells compared with IFN-alpha. Antiviral Res. 2017; 140: 76–82. doi: 10.1016/j.antiviral.2017.01.012Li L., Fu F., Xue M., Chen W., Liu J., Shi H., Chen J., Bu Z., Feng L., Liu P. IFN-lambda preferably inhibits PEDV infection of porcine intestinal epithelial cells compared with IFN-alpha. Antiviral Res. 2017; 140: 76–82. doi: 10.1016/j.antiviral.2017.01.012Li Z., Lu X., Zhu Y., Cheng P., Liu S., Zhang Y., Tang J., Yang S., Zhou L. Lambda-interferons inhibit herpes simplex virus type 2 replication in human cervical epithelial cells by activating the JAK/STAT pathway. Jpn. J. Infec. Dis. 2017; 70 (4): 416–422. doi:10.7883/yoken.JJID.2016.465Li Z., Lu X., Zhu Y., Cheng P., Liu S., Zhang Y., Tang J., Yang S., Zhou L. Lambda-interferons inhibit herpes simplex virus type 2 replication in human cervical epithelial cells by activating the JAK/STAT pathway. Jpn. J. Infec. Dis. 2017; 70 (4): 416–422. doi:10.7883/yoken.JJID.2016.465Luo Q., Liu Y., Liu S., Yin Y., Xu B., Cao J. Interleukin 28 is a potential therapeutic target for sepsis. Clin. Immunol. 2019; 205: 29–34. doi: 10.1016/j.clim.2019.05.012Luo Q., Liu Y., Liu S., Yin Y., Xu B., Cao J. Interleukin 28 is a potential therapeutic target for sepsis. Clin. Immunol. 2019; 205: 29–34. doi: 10.1016/j.clim.2019.05.012Mordstein M., Kochs G., Dumoutier L., Renauld J.C., Paludan S.R., Klucher K., Staeheli P. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 2008; 4. e1000151. doi: 10.1371/journal.ppat.1000151Mordstein M., Kochs G., Dumoutier L., Renauld J.C., Paludan S.R., Klucher K., Staeheli P. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 2008; 4. e1000151. doi: 10.1371/journal.ppat.1000151Mordstein M., Neugebauer E., Ditt V., Jessen B., Rieger T., Falcone V., Sorgeloos F., Ehl S., Mayer D., Kochs G. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 2010; 84: 5670–5677. doi:10.1128/JVI.00272-10Mordstein M., Neugebauer E., Ditt V., Jessen B., Rieger T., Falcone V., Sorgeloos F., Ehl S., Mayer D., Kochs G. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 2010; 84: 5670–5677. doi:10.1128/JVI.00272-10Mucha J., Majchrzak K., Taciak B., Hellmén E., Król M. MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/ IL-28RA (IFN-λ) signaling. PLoS ONE. 2014; 9 (7): e103249. doi: 10.1371/journal.pone.0103249Mucha J., Majchrzak K., Taciak B., Hellmén E., Król M. MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/ IL-28RA (IFN-λ) signaling. PLoS ONE. 2014; 9 (7): e103249. doi: 10.1371/journal.pone.0103249Muir A.J., Arora S., Everson G., Flisiak R., George J., Ghalib R., Gordon S.C., Gray T., Greenbloom S., Hassanein T., Hillson J., Horga M.A., Jacobson I.M., Jeffers L., Kowdley K.V., Lawitz E., Lueth S., Rodriguez-Torres M., Rustgi V., Shemanski L., Shiffman M.L., Srinivasan S., Vargas H.E., Vierling J.M., Xu D., Lopez-Talavera J.C., Zeuzem S. EMERGE study group. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J. Hepatol. 2014; 61 (6). 1238–1246. doi: 10.1016/j.jhep.2014.07.022Muir A.J., Arora S., Everson G., Flisiak R., George J., Ghalib R., Gordon S.C., Gray T., Greenbloom S., Hassanein T., Hillson J., Horga M.A., Jacobson I.M., Jeffers L., Kowdley K.V., Lawitz E., Lueth S., Rodriguez-Torres M., Rustgi V., Shemanski L., Shiffman M.L., Srinivasan S., Vargas H.E., Vierling J.M., Xu D., Lopez-Talavera J.C., Zeuzem S. EMERGE study group. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J. Hepatol. 2014; 61 (6). 1238–1246. doi: 10.1016/j.jhep.2014.07.022Nelson M., Rubio R., Lazzarin A., Romanova S., Luetkemeyer A., Conway B., Molina J.M., Xu D., Srinivasan S., Portsmouth S. Safety and efficacy of pegylated interferon lambda, ribavirin, and daclatasvir in HCV and HIV-coinfected patients. J. Interferon Cytokine Res. 2017; 37 (3): 103–111. doi:10.1089/jir.2016.0082Nelson M., Rubio R., Lazzarin A., Romanova S., Luetkemeyer A., Conway B., Molina J.M., Xu D., Srinivasan S., Portsmouth S. Safety and efficacy of pegylated interferon lambda, ribavirin, and daclatasvir in HCV and HIV-coinfected patients. J. Interferon Cytokine Res. 2017; 37 (3): 103–111. doi:10.1089/jir.2016.0082Nice T.J., Baldridge M.T., McCune B.T., Norman J.M., Lazear H.M., Artyomov M., Diamond M.S., Virgin H.W. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science. 2015; 347: 269–273. doi: 10.1126/science.1258100Nice T.J., Baldridge M.T., McCune B.T., Norman J.M., Lazear H.M., Artyomov M., Diamond M.S., Virgin H.W. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science. 2015; 347: 269–273. doi: 10.1126/science.1258100O’Brien T.R., Young H.A., Donnelly R.P., Prokunina-Olsson L. Meeting overview: interferon lambda-disease impact and therapeutic potential. J. Interferon Cytokine Res. 2019. 39 (10): 586–591. doi:10.1089/jir.2019.0018O’Brien T.R., Young H.A., Donnelly R.P., Prokunina-Olsson L. Meeting overview: interferon lambda-disease impact and therapeutic potential. J. Interferon Cytokine Res. 2019. 39 (10): 586–591. doi:10.1089/jir.2019.0018Oke V., Brauner S., Larsson A., Gustafsson J., Zickert A., Gunnarsson I., Svenungsson E. IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE). Arthritis Res. Ther. 2017; 19 (1): 139–151. doi: 10.1186/s13075-0171344-7Oke V., Brauner S., Larsson A., Gustafsson J., Zickert A., Gunnarsson I., Svenungsson E. IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE). Arthritis Res. Ther. 2017; 19 (1): 139–151. doi: 10.1186/s13075-0171344-7Phillips S., Mistry S., Riva A., Cooksley H., Hadzhiolova-Lebeau T., Plavova S., Katzarov K., Simonova M., Zeuzem S., Woffendin C., Chen P.J., Peng C.Y., Chang T.T., Lueth S., de Knegt R., Choi M.S., Wedemeyer H., Dao M., Kim C.W., Chu H.C., Wind-Rotolo M., Williams R., Cooney E., Chokshi S. Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis b patients. Front. Immunol. 2017; 8: 621. doi: 10.3389/fimmu.2017.00621Phillips S., Mistry S., Riva A., Cooksley H., Hadzhiolova-Lebeau T., Plavova S., Katzarov K., Simonova M., Zeuzem S., Woffendin C., Chen P.J., Peng C.Y., Chang T.T., Lueth S., de Knegt R., Choi M.S., Wedemeyer H., Dao M., Kim C.W., Chu H.C., Wind-Rotolo M., Williams R., Cooney E., Chokshi S. Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis b patients. Front. Immunol. 2017; 8: 621. doi: 10.3389/fimmu.2017.00621Planet P.J., Parker D., Cohen T.S., Smith H., Leon J.D., Ryan C., Hammer T.J., Fierer N., Chen E.I., Prince A.S. Lambda interferon restructures the nasal microbiome and increases susceptibility to Staphylococcus aureus superinfection. MBio. 2016; 7 (1): e01939-15. doi: 10.1128/mBio.01939-15Planet P.J., Parker D., Cohen T.S., Smith H., Leon J.D., Ryan C., Hammer T.J., Fierer N., Chen E.I., Prince A.S. Lambda interferon restructures the nasal microbiome and increases susceptibility to Staphylococcus aureus superinfection. MBio. 2016; 7 (1): e01939-15. doi: 10.1128/mBio.01939-15Pott J., Mahlakoiv T., Mordstein M., Duerr C.U., Michiels T., Stockinger S., Staeheli P., Hornef M.W. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. USA. 2011; 108 (19): 7944–7949. doi: 10.1073/pnas.1100552108Pott J., Mahlakoiv T., Mordstein M., Duerr C.U., Michiels T., Stockinger S., Staeheli P., Hornef M.W. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. USA. 2011; 108 (19): 7944–7949. doi: 10.1073/pnas.1100552108Rich H.E., McCourt C.C., Zheng W.Q., McHugh K.J., Robinson K.M., Wang J., Alcorn J.F. Interferon lambda inhibits bacterial uptake during influenza superinfection. Infect. Immun. 2019. 87 (5): e00114–19. doi: 10.1128/IAI.00114-19Rich H.E., McCourt C.C., Zheng W.Q., McHugh K.J., Robinson K.M., Wang J., Alcorn J.F. Interferon lambda inhibits bacterial uptake during influenza superinfection. Infect. Immun. 2019. 87 (5): e00114–19. doi: 10.1128/IAI.00114-19Rivera A. Interferon lambda’s new role as regulator of neutrophil function. J. Interferon Cytokine Res. 2019. 39 (10): 609–617. doi: 10.1089/jir.2019.0036Rivera A. Interferon lambda’s new role as regulator of neutrophil function. J. Interferon Cytokine Res. 2019. 39 (10): 609–617. doi: 10.1089/jir.2019.0036Rocha-Pereira J., Jacobs S., Noppen S., Verbeken E., Michiels T., Neyts J. Interferon lambda (IFN-λ) efficiently blocks norovirus transmission in a mouse model. Antiviral Res. 2018; 149: 7–15. doi:10.1016/j.antiviral.2017Rocha-Pereira J., Jacobs S., Noppen S., Verbeken E., Michiels T., Neyts J. Interferon lambda (IFN-λ) efficiently blocks norovirus transmission in a mouse model. Antiviral Res. 2018; 149: 7–15. doi:10.1016/j.antiviral.2017Sauerhering L., Müller H., Behner L., Elvert M., Fehling S.K., Strecker T., Maisner A. Variability of interferon-λ induction and antiviral activity in Nipah virus infected differentiated human bronchial epithelial cells of two human donors. J. Gen. Virol. 2017; 98 (10): 2447–2453. doi: 10.1099/jgv.0.000934Sauerhering L., Müller H., Behner L., Elvert M., Fehling S.K., Strecker T., Maisner A. Variability of interferon-λ induction and antiviral activity in Nipah virus infected differentiated human bronchial epithelial cells of two human donors. J. Gen. Virol. 2017; 98 (10): 2447–2453. doi: 10.1099/jgv.0.000934Sheppard P.O., Fox B.A., Klucher K.M., Taft D.W., Kindsvogel W.R. Cytokine protein family. Patent WO2002086087 US; Publ. 31.10.2002.Sheppard P.O., Fox B.A., Klucher K.M., Taft D.W., Kindsvogel W.R. Cytokine protein family. Patent WO2002086087 US; Publ. 31.10.2002.Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F.J., Tackett M., Krivan W., Mcknight G., Clegg C., Foster D., Klucher K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003; 4: 63–68. doi: 10.1038/ni873Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F.J., Tackett M., Krivan W., Mcknight G., Clegg C., Foster D., Klucher K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003; 4: 63–68. doi: 10.1038/ni873Swamy M., Abeler-Dörner L., Chettle J., Mahlakõiv T., Goubau D., Chakravarty P., Ramsay G., Reis E., Sousa C., Staeheli P., Blacklaws B.A., Heeney J.L., Hayday A.C. Intestinal intraepithelial lymphocyte activation promotes innate antiviral resistance. Nat. Commun. 2015; 6: 7090. doi: 10.1038/ncomms8090Swamy M., Abeler-Dörner L., Chettle J., Mahlakõiv T., Goubau D., Chakravarty P., Ramsay G., Reis E., Sousa C., Staeheli P., Blacklaws B.A., Heeney J.L., Hayday A.C. Intestinal intraepithelial lymphocyte activation promotes innate antiviral resistance. Nat. Commun. 2015; 6: 7090. doi: 10.1038/ncomms8090Taniguchi M., Yanagi Y., Ohno S. Both type I and type III interferons are required to restrict measles virus growth in lung epithelial cells. Arch. Virol. 2019; 164 (2): 439–446. doi: 10.1007/s00705-018-4087-0Taniguchi M., Yanagi Y., Ohno S. Both type I and type III interferons are required to restrict measles virus growth in lung epithelial cells. Arch. Virol. 2019; 164 (2): 439–446. doi: 10.1007/s00705-018-4087-0Wang X., Wang H., Liu M.Q., Li J.L., Zhou R.H., Zhou Y., Wang Y.Z., Zhou W., Ho W.Z. IFN-λ inhibits drug-resistant HIV infection of macrophages. Front. Immunol. 2017; 8: 210. doi: 10.3389/fimmu.2017.00210Wang X., Wang H., Liu M.Q., Li J.L., Zhou R.H., Zhou Y., Wang Y.Z., Zhou W., Ho W.Z. IFN-λ inhibits drug-resistant HIV infection of macrophages. Front. Immunol. 2017; 8: 210. doi: 10.3389/fimmu.2017.00210Wieland S.F., Heim M.H. The IFN-λ pony express. Nat. Immunol. 2019; 20 (5): 522–524. doi:10.1038/s41590-019-0362-9Wieland S.F., Heim M.H. The IFN-λ pony express. Nat. Immunol. 2019; 20 (5): 522–524. doi:10.1038/s41590-019-0362-9Wolk K., Witte K., Witte E., Raftery M., Kokolakis G., Philipp S., Schonrich G., Warszawska K., Kirsch S., Prosch S., Sterry W., Volk H.D., Sabat R. IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci. Transl. Med. 2013; 5 (204): 204–129. doi: 10.1126/scitranslmed.3006245Wolk K., Witte K., Witte E., Raftery M., Kokolakis G., Philipp S., Schonrich G., Warszawska K., Kirsch S., Prosch S., Sterry W., Volk H.D., Sabat R. IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci. Transl. Med. 2013; 5 (204): 204–129. doi: 10.1126/scitranslmed.3006245Won J., Gil C.H., Jo A., Kim H.J. Inhaled delivery of Interferon-lambda restricts epithelial-derived Th2 inflammation in allergic asthma. Cytokine. 2019; 119: 32–36. doi: 10.1016/j.cyto.2019.02.010Won J., Gil C.H., Jo A., Kim H.J. Inhaled delivery of Interferon-lambda restricts epithelial-derived Th2 inflammation in allergic asthma. Cytokine. 2019; 119: 32–36. doi: 10.1016/j.cyto.2019.02.010Wongthida P., Diaz R.M., Galivo F., Kottke T., Thompson J., Pulido J., Pavelko K., Pease L., Melcher A., Vile R. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immunecompetent mouse models of cancer. Cancer Res. 2010; 70 (11): 4539–4549. doi: 10.1158/0008-5472.CAN-094658Wongthida P., Diaz R.M., Galivo F., Kottke T., Thompson J., Pulido J., Pavelko K., Pease L., Melcher A., Vile R. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immunecompetent mouse models of cancer. Cancer Res. 2010; 70 (11): 4539–4549. doi: 10.1158/0008-5472.CAN-094658Yang K., Puel A., Zhang S., Eidenschenk C., Ku C.L., Casrouge A., Picard C., von Bernuth H., Senechal B., Plancoulaine S., Al-Hajjar S., Al-Ghonaium A., Maródi L., Davidson D., Speert D., Roifman C., Garty B.Z., Ozinsky A., Barrat F.J., Coffman R.L., Miller R.L., Li X., Lebon P., Rodriguez-Gallego C., Chapel H., Geissmann F., Jouanguy E., Casanova J.L. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/ beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity. 2005; 23 (5): 465–478. doi: 10.1016/j.immuni.2005.09.016Yang K., Puel A., Zhang S., Eidenschenk C., Ku C.L., Casrouge A., Picard C., von Bernuth H., Senechal B., Plancoulaine S., Al-Hajjar S., Al-Ghonaium A., Maródi L., Davidson D., Speert D., Roifman C., Garty B.Z., Ozinsky A., Barrat F.J., Coffman R.L., Miller R.L., Li X., Lebon P., Rodriguez-Gallego C., Chapel H., Geissmann F., Jouanguy E., Casanova J.L. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/ beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity. 2005; 23 (5): 465–478. doi: 10.1016/j.immuni.2005.09.016Ye L., Schnepf D., Becker J., Ebert K., Tanriver Y., Bernasconi V., Gad H.H., Hartmann R., Lycke N., Staeheli P. Interferon-λ enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin. Nat. Immunol. 2019; 20 (5): 593–601. doi: 10.1038/s41590-019-0345-xYe L., Schnepf D., Becker J., Ebert K., Tanriver Y., Bernasconi V., Gad H.H., Hartmann R., Lycke N., Staeheli P. Interferon-λ enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin. Nat. Immunol. 2019; 20 (5): 593–601. doi: 10.1038/s41590-019-0345-xYu D., Zhao M., Dong L., Zhao L., Zou M., Sun H., Zhang M., Liu H., Zou Z. Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes . Drug. Des. Devel. Ther. 2016; 10: 163–182. doi: 10.2147/DDDT.S91455Yu D., Zhao M., Dong L., Zhao L., Zou M., Sun H., Zhang M., Liu H., Zou Z. Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes . Drug. Des. Devel. Ther. 2016; 10: 163–182. doi: 10.2147/DDDT.S91455

The authors declare that there are no conflicts of interest present.